[Form 4] Agios Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Theodore James Jr., identified as a Principal Accounting Officer of Agios Pharmaceuticals (AGIO), reported a sale of 8,546 shares of the issuer's common stock on 09/05/2025 at a reported price of $36.87 per share. After the reported transaction, the filing shows 868 shares beneficially owned by the reporting person in a direct form. The disclosure is a standard Section 16 Form 4 reporting an insider sale.

Insights

Financial Analyst

TL;DR: Routine insider sale disclosed; transaction size appears modest relative to typical executive holdings.

The Form 4 documents a sale of 8,546 shares at $36.87, leaving 868 shares beneficially owned directly. This is a straightforward Section 16 disclosure that provides transparency on insider activity but contains no additional company financial data or indications of changed ownership control. Without context on total outstanding shares or the executive's prior holdings, the sale alone is not sufficient to infer material impact on valuation.

Corporate Governance Expert

TL;DR: Compliance with SEC disclosure rules appears satisfied; filing shows an executed insider sale with appropriate reporting.

The document names the reporting person and their corporate role, specifies the transaction type (sale), the number of shares sold, the price per share, and the remaining direct ownership. The filing includes a signature executed by an attorney-in-fact, indicating standard procedural handling. There are no disclosures of derivative transactions or related-party arrangements in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Washburn Theodore James Jr.

(Last) (First) (Middle)

88 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	09/05/2025		S		8,546	D	$36.87	868	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ William Cook, as attorney-in-fact for Theodore James Jr. Washburn	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AGIO insider Theodore James Jr. report on Form 4?

The Form 4 reports a sale of 8,546 shares of Agios Pharmaceuticals common stock.

When was the insider sale reported to have occurred for AGIO?

The reported transaction date is 09/05/2025.

At what price were the AGIO shares sold by the reporting person?

The sale price reported is $36.87 per share.

How many AGIO shares does Theodore James Jr. beneficially own after the transaction?

The Form 4 shows 868 shares beneficially owned following the reported sale.

What is Theodore James Jr.'s role at Agios Pharmaceuticals as listed on the Form 4?

He is listed as a Principal Accounting Officer and the filing indicates officer status.